EKEmma Kennedy

Emma Kennedy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emma Kennedy has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunogenicity and protective efficacy of single-dose adenoviral vaccines expressing Crimean-Congo haemorrhagic fever virus GP38, Gc, or nucleoprotein antigens in mice: a preclinical study

    by Jack E. Saunders, Ciaran Gilbride, Alex Sampson, Stuart Dowall, Emma Kennedy, Sarah Webster, Susan Fotheringham, Stephen Findlay–Wilson, Fahad Al-Dainy, Susana Camara, et al.

  • Open Access

    Defining Challenge Conditions for Nipah Virus in the Syrian Golden Hamster Model: Effects of Dose, Exposure Route and Viral Strain

    by Emma Kennedy, Stephen Findlay-Wilson, Francisco J. Salguero, Ines Ruedas-Torres, Susan Fotheringham, Linda Easterbrook, Victoria A. Graham, Sarah Kempster, Neil Almond, Stuart D. Dowall

    Nipah virus (NiV) is a highly pathogenic zoonotic virus for which no licensed vaccines or therapeutics are currently available, necessitating well-characterised animal models to support countermeasure development. This study aimed to establish an appropriate challenge dose in the Syrian golden hamster model at the UK Health Security Agency (UKHSA), incorporating both intraperitoneal (i.p.) and intranasal (i.n.) routes of infection and two clinically relevant strains, NiV-Malaysia (NiV-M) and NiV-Bangladesh (NiV-B). Due to a different challenge doses and susceptibilities of hamsters to NiV being reported in the literature, there is a prerequisite to define the model parameters upon establishment in a new facility. Dose-ranging studies were performed across multiple independent experiments assessing survival, clinical progression and histopathological outcomes. Challenge via the i.p. route produced consistent and severe disease using an infectious dose of 103 TCID50 for both strains. In contrast, animals were more susceptible to infection via i.n. challenge with a dose of 10 TCID50 resulting in uniform lethality. For both challenge routes, respiratory and neurological disease manifestations were observed. These distinct disease phenotypes were supported by histopathological findings and viral RNA distribution in affected organs. Differences between strains were evident, with NiV-B showing a tendency towards a broader pulmonary pathology at lower doses after i.n. challenge. Collectively, these findings demonstrate that challenge dose, route of exposure, and viral strain influence disease outcomes in the hamster model.

  • Open Access

    Preclinical Models of Oropouche Virus Infection and Disease

    by Daniel Morley, Emma Kennedy, Stuart Dowall

    Oropouche virus (OROV) is an emerging and underreported arbovirus with dengue-like symptoms confounding diagnosis. OROV is also neuroinvasive, with a small number of cases presenting severe neurological symptoms. There have been recently reported deaths from confirmed cases of OROV and reported instances of vertical transmission from mother to foetus, with confirmed cases in Brazil and a congenital anomaly, reportedly as a consequence of OROV infection in Cuba, with further cases under investigation. Whilst cases of OROV infection occur mainly in South America, many cases have been imported elsewhere, including the United States and Europe. Despite the emerging threat to public health, animal modelling to study OROV pathogenicity and immunity and to evaluate therapeutic candidates remains limited. For this review, we carried out a literature search through major research databases (PubMed and Scopus) up to September 2025 to capture the extent of in vivo model development for this pathogen. We identified only 17 relevant primary research articles within these criteria which detailed hamster, mouse and non-human primate (NHP) models. Here, we discuss the extent of in vivo model development for OROV. In summary, small and large animal models need to be assessed with recent clinical isolates and reassortants, asymptomatic disease presentation in the NHP model requires further study and the hamster model shows potential for use in pathogenicity and vaccine or antiviral efficacy studies. We also compile relevant metadata and discuss the need for an animal model that more closely resembles human disease.


  • Open Access

    Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine

    by Martina Pfranger, Nina Krause, Benedikt Asbach, Johannes Meier, George Carnell, Lara Scheer, Anja Kalender, David Brenner, Paul Tonks, Simon Frost, et al.

    A multivalent vaccine targeting high-consequence infectious diseases in Sub-Saharan Africa (SSA), which are linked to high mortality, morbidity and overlapping clinical manifestations, would significantly improve health security and economic stability in this region. Trivalent vector vaccines were devised to deliver digitally optimized versions of Orthoebolavirus, Orthomarburgvirus glycoproteins (GPs) and a Lassa mammarenavirus (LASV) nucleoprotein (NP) by a single Modified Vaccinia Ankara (MVA) known to protect against mpox virus (MPXV) along with a matched DNA vaccine. Three immunizations in mice and Hartley guinea pigs with MVA only or a DNA prime followed by two MVA administrations induced comparable levels of binding antibodies and LASV-specific T-cells, respectively. While DNA priming mitigated MVA-specific antibody responses, GP- and NP-specific antibodies developed already after a single MVA vaccination. Although a post-outbreak Ebola virus vaccine is available, outbreaks by other filoviruses, annual LASV epidemics and increased incidence of MPXV infections support the rationale for an MVA-based trivalent haemorrhagic fever vaccine for endemic and high-risk human populations in SSA.


  • Open Access

    Susceptibility and transmission of mpox virus infection in brown rats (Rattus norvegicus)

    by Lucy Crossley, Stephen Findlay-Wilson, Linda Easterbrook, Emma Kennedy, Francisco J. Salguero, Kim Mackay, Victoria Graham, Susan Fotheringham, Stuart Dowall

    A corrigendum of this article has been published full details can be found at https://doi.org/10.1099/jgv.0.002162 . Mpox (formerly known as monkeypox) virus (MPXV) is the zoonotic pathogen of mpox disease in humans. Its increasing emergence outside of its endemic area has heightened the importance of investigating the virus’ prevalence and maintenance in sylvatic reservoirs. The common brown rat (Rattus norvegicus) can inhabit almost anywhere in the UK, posing a threat to zoonotic transmission to humans. Two independent studies were carried out; the first investigated the susceptibility of brown rats to MPXV infection with a clade IIb mpox strain via two challenge routes: intranasal and intradermal. The second study considered the transmission of MPXV between challenged and naïve brown rats. All animals were asymptomatic to mpox disease, although enzyme-linked immunosorbent assay (ELISA) confirmed subclinical infection in challenge groups. In the susceptibility study, reverse transcription PCR (RT-PCR) detected mpox DNA in the lung tissue and throat swabs within the intranasally inoculated group, in addition to viable virus observed from the intranasal throat swabs. In contrast, no virus was detected in either tissues or swabs in the intradermally inoculated group or control group. RT-PCR results from the transmission study detected mpox DNA in tissues and throat swabs taken from challenged animals. Viable virus was observed from tissues and swabs of intranasally challenged animals with infectious titres of ~102–104 TCID50 per millilitre. ELISA assays in the transmission study showed replicable results compared to the first susceptibility study in directly challenged animals alongside evidence of seroconversion in co-housed naïve animals. In conclusion, brown rats are susceptible to MPXV infection, as they have been demonstrated to maintain viable virus in the absence of clinical signs. Viral transmission of MPXV from infected rats to naïve rats was not observed by RT-PCR, although naïve rats did show antibody responses when exposed to infected rats indicating exposure to virus.


  • Open Access

    A Multi-Valent Hantavirus Vaccine Based on Recombinant Modified Vaccinia Ankara Reduces Viral Load in a Mouse Infection Model

    by Marilyn Aram, Victoria Graham, Emma Kennedy, Emma Rayner, Roger Hewson, Stuart Dowall

    Background: Old World orthohantaviruses are the aetiological agent of Haemorrhagic Fever with Renal Syndrome (HFRS) disease. Worldwide, the two most prominent pathogens of HFRS are Seoul orthohantavirus (SEOV) and Hantaan orthohantavirus (HTNV). There is currently no specific treatment nor widely licensed vaccine form hantaviruses. Methods: This study developed a virus-vectored vaccine approach using modified vaccinia Ankara (MVA) incorporating a SEOV-HTNV chimeric nucleoprotein antigen. Results: The vaccine demonstrated the induction of humoral and cellular immunity. In the absence of a disease model, a reduction in the viral load of a susceptible mouse strain with type-I interferon receptor deficiency (A129) was used to ascertain protective effects after challenge with SEOV. Results demonstrated a significant reduction in and/or clearance of viral RNA in immunised animals. Conclusions: An MVA viral vector vaccine incorporating the nucleoprotein as antigen offers a promising approach for Hantavirus vaccine development.


  • Open Access

    A Review of Nonhuman Primate Models of Rift Valley Fever Virus Infection: Progress, Challenge Strains, and Future Directions

    by Kimimuepigha Ebisine, Darcy Quist, Stephen Findlay-Wilson, Emma Kennedy, Stuart Dowall

    Rift Valley fever (RVF) is a mosquito-borne viral disease that primarily affects animals, especially ruminants, but has the capacity to infect humans and result in outbreaks. Infection with the causative agent, RVF virus (RVFV), causes severe disease in domestic animals, especially sheep, resulting in fever, anorexia, immobility, abortion, and high morbidity and mortality rates in neonate animals. Humans become infected through exposure to infected animals and, less frequently, directly via a mosquito bite. A greater awareness of RVFV and its epidemic potential has resulted in increased investment in the development of interventions, especially vaccines. There is currently no substitute for the use of animal models in order to evaluate these vaccines. As outbreaks of RVF disease are difficult to predict or model, conducting Phase III clinical trials will likely not be feasible. Therefore, representative animal model systems are essential for establishing efficacy data to support licensure. Nonhuman primate (NHP) species are often chosen due to their closeness to humans, reflecting similar susceptibility and disease kinetics. This review covers the use of NHP models in RVFV research, with much of the work having been conducted in rhesus macaques and common marmosets. The future direction of RVF work conducted in NHP is discussed in anticipation of the importance of it being a key element in the development and approval of a human vaccine.


  • Open Access

    Comparison of Chikungunya Virus-Induced Disease Progression and Pathogenesis in Type-I Interferon Receptor-Deficient Mice (A129) and Two Wild-Type (129Sv/Ev and C57BL/6) Mouse Strains

    by Victoria A. Graham, Linda Easterbrook, Emma Rayner, Stephen Findlay-Wilson, Lucy Flett, Emma Kennedy, Susan Fotheringham, Sarah Kempster, Neil Almond, Stuart Dowall

    Chikungunya virus (CHIKV) is a mosquito-borne alphavirus causing a debilitating febrile illness with rheumatic disease symptoms of arthralgia and arthritis. Since its spread outside of Africa in 2005, it continues to cause outbreaks and disseminates into new territories. Intervention strategies are urgently required, including vaccination and antiviral approaches. To test efficacy, the use of small animal models is required. Two mouse strains, A129, with a deficiency in their type-I interferon (IFN) receptor, and C57BL/6 are widely used. A direct comparison of these strains alongside the wild-type parental strain of the A129 mice, 129Sv/Ev, was undertaken to assess clinical disease progression, viral loads in key tissues, histological changes and levels of sera biomarkers. Our results confirm the severe disease course in A129 mice which was not observed in the parental 129Sv/Ev strain. Of the two wild-type strains, viral loads were higher in 129Sv/Ev mice compared to C57BL/6 counterparts. Our results have established these models and parameters for the future testing of vaccines and antiviral approaches.


  • Open Access

    Convalescent human plasma candidate reference materials protect against Crimean-Congo haemorrhagic fever virus (CCHFV) challenge in an A129 mouse model

    by Sarah Kempster, Mark Hassall, Victoria Graham, Emma Kennedy, Stephen Findlay-Wilson, Francisco J. Salguero, Binnur Bagci, Nazif Elaldi, Murtaza Oz, Tuba Tasseten, et al.


  • Open Access

    Pathogenesis of Rift Valley Fever Virus in a BALB/c Mouse Model Is Affected by Virus Culture Conditions and Sex of the Animals

    by Victoria A. Graham, Linda Easterbrook, Emma Kennedy, Emma Rayner, Stephen Findlay-Wilson, Lucy Flett, Emma Louise Wise, Samantha Treagus, Susan Fotheringham, Sarah Kempster, et al.

    Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen causing disease in livestock and humans. Whilst initially restricted to the African continent, recent spread to the Arabian Peninsula has highlighted the likelihood of entry into new regions. Due to the absence of a regulatory-approved human vaccine, work is ongoing to develop and assess countermeasures. As such, small animal models play a pivotal role in providing information on disease pathogenesis and elucidating which intervention strategies confer protection. To develop and establish the BALB/c mouse model, we challenged mice with RVFV grown from two separate cell lines: one derived from mosquitoes (C6/36) and the other mammalian derived (Vero E6). Following infection, we assessed the clinical course of disease progression at days 1 and 3 post-challenge and evaluated viral tropism and immune analytes. The results demonstrated that RVFV infection was affected by the cell line used to propagate the challenge virus, with those grown in insect cells resulting in a more rapid disease progression. The lowest dose that caused uniform severe disease remained the same across both virus preparations. In addition, to demonstrate reproducibility, the lowest dose was used for a subsequent infection study using male and female animals. The results further demonstrated that male mice succumbed to infection more rapidly than their female counterparts. Our results establish an RVFV mouse model and key parameters that affect the course of disease progression in BALB/c mice.